McDougle C J, Barr L C, Goodman W K, Pelton G H, Aronson S C, Anand A, Price L H
Department of Psychiatry, Yale University School of Medicine, New Haven, Conn., USA.
Am J Psychiatry. 1995 Dec;152(12):1812-4. doi: 10.1176/ajp.152.12.1812.
The authors assessed the efficacy of clozapine monotherapy for adults with treatment-resistant obsessive-compulsive disorder.
Twelve adults with refractory obsessive-compulsive disorder participated in a 10-week, open-label, systematic trial of clozapine. They were assessed with the Yale-Brown Obsessive Compulsive Scale, the Hamilton Depression Rating Scale, and the global improvement item of the Clinical Global Impression (CGI) scale.
None of the 10 patients who completed the trial was a responder. No significant change was observed in obsessive-compulsive or depressive symptoms or in scores on the CGI global improvement item.
These findings suggest that clozapine monotherapy is not effective for most adult patients with treatment-resistant obsessive-compulsive disorder.
作者评估了氯氮平单药治疗对难治性强迫症成年患者的疗效。
12名难治性强迫症成年患者参与了一项为期10周的氯氮平开放标签系统性试验。使用耶鲁-布朗强迫症量表、汉密尔顿抑郁量表以及临床总体印象量表（CGI）的总体改善项目对他们进行评估。
完成试验的10名患者中无一例有反应。强迫症或抑郁症状以及CGI总体改善项目评分均未观察到显著变化。
这些发现表明，氯氮平单药治疗对大多数难治性强迫症成年患者无效。
